RARA CRAFT DATABASE for FDA Medical Devices
510(k)K230990

FDA DEVICE FACTS

Candela Vbeam Family of Pulsed Dye Lasers (Vbeam Prima, Vbeam Perfecta)

Candela Corporation

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEJune 1, 2023PRODUCT CODEGEX

Indications for use

Vbeam Prima: Vbeam Prima is indicated for the following: 595 nm x General Surgery: x Photocoagulation of benign cutaneous vascular lesions and benign cutaneous lesions. x Dermatology/Plastic Surgery: o For treatment of benign cutaneous vascular lesions, such as facial and leg telangiectasia, rosacea, port wine stains, hemangiomas, angioma, spider angioma, Poikiloderma of Civatte, and benign cutaneous lesions, such as warts, scars, striae and Psoriasis and the treatment of wrinkles. x Treatment of Benign Epidermal Pigmented Lesions. x Treatment of Inflammatory Acne Vulgaris. x Gynecology: o Photocoagulation of benign cutaneous lesions and benign vascular lesions in gynecology. x Podiatry: o Treatment of benign cutaneous lesions, such as warts. x Pediatric Population o Treatment of cutaneous capillary malformations, also known as port wine stains (PWS), and infantile hemangiomas (IH) / congenital hemangiomas 1064 nm The Vbeam Prima laser system is intended for the coagulation and hemostasis of benign vascular lesions such as, but not limited to, port wine stains, hemangiomas, warts, telangiectasia, rosacea, Venus lakes, leg veins, spider veins, and poikiloderma of Civatte and treatment of benign cutaneous lesions such as, but not limited to lentigos (age spots), solar lentigos (sun spots), café-au-lait macules, seborrheic keratoses, nevi, chloasma, verrucae, skin tags, and keratoses. The laser is also indicated for the treatment of wrinkles such as, but not limited to, peri-ocular and peri-oral wrinkles. Vbeam Perfecta: Vbeam Perfecta is indicated for the following: 595 nm x General Surgery: x Photocoagulation of benign cutaneous vascular lesions and benign cutaneous lesions. x Dermatology/Plastic Surgery: o For treatment of benign cutaneous vascular lesions, such as facial and leg telangiectasia, rosacea, port wine stains, hemangiomas, angioma, spider angioma, Poikiloderma of Civatte, and benign cutaneous lesions, such as warts, scars, striae and Psoriasis and the treatment of wrinkles. x Treatment of Benign Epidermal Pigmented Lesions. x Treatment of Inflammatory Acne Vulgaris. x Gynecology: o Photocoagulation of benign cutaneous lesions and benign vascular lesions in gynecology. x Podiatry: o Treatment of benign cutaneous lesions, such as warts. x Pediatric Population o Treatment of cutaneous capillary malformations, also known as port wine stains (PWS), and infantile hemangiomas (IH) / congenital hemangiomas

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 18, 2026